Literature DB >> 24285728

Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

Joanne R Doherty1, Chunying Yang, Kristen E N Scott, Michael D Cameron, Mohammad Fallahi, Weimin Li, Mark A Hall, Antonio L Amelio, Jitendra K Mishra, Fangzheng Li, Mariola Tortosa, Heide Marika Genau, Robert J Rounbehler, Yunqi Lu, Chi V Dang, K Ganesh Kumar, Andrew A Butler, Thomas D Bannister, Andrea T Hooper, Keziban Unsal-Kacmaz, William R Roush, John L Cleveland.   

Abstract

Myc oncoproteins induce genes driving aerobic glycolysis, including lactate dehydrogenase-A that generates lactate. Here, we report that Myc controls transcription of the lactate transporter SLC16A1/MCT1 and that elevated MCT1 levels are manifest in premalignant and neoplastic Eμ-Myc transgenic B cells and in human malignancies with MYC or MYCN involvement. Notably, disrupting MCT1 function leads to an accumulation of intracellular lactate that rapidly disables tumor cell growth and glycolysis, provoking marked alterations in glycolytic intermediates, reductions in glucose transport, and in levels of ATP, NADPH, and ultimately, glutathione (GSH). Reductions in GSH then lead to increases in hydrogen peroxide, mitochondrial damage, and ultimately, cell death. Finally, forcing glycolysis by metformin treatment augments this response and the efficacy of MCT1 inhibitors, suggesting an attractive combination therapy for MYC/MCT1-expressing malignancies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24285728      PMCID: PMC3946415          DOI: 10.1158/0008-5472.CAN-13-2034

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression.

Authors:  P Kirk; M C Wilson; C Heddle; M H Brown; A N Barclay; A P Halestrap
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

2.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

Authors:  C M Eischen; J D Weber; M F Roussel; C J Sherr; J L Cleveland
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

3.  Cell cycle activation by c-myc in a burkitt lymphoma model cell line.

Authors:  A Pajic; D Spitkovsky; B Christoph; B Kempkes; M Schuhmacher; M S Staege; M Brielmeier; J Ellwart; F Kohlhuber; G W Bornkamm; A Polack; D Eick
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

4.  DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.

Authors:  Pascale Fisel; Stephan Kruck; Stefan Winter; Jens Bedke; Jörg Hennenlotter; Anne T Nies; Marcus Scharpf; Falko Fend; Arnulf Stenzl; Matthias Schwab; Elke Schaeffeler
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

5.  Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation.

Authors:  S R Frank; M Schroeder; P Fernandez; S Taubert; B Amati
Journal:  Genes Dev       Date:  2001-08-15       Impact factor: 11.361

6.  Repression of p15INK4b expression by Myc through association with Miz-1.

Authors:  P Staller; K Peukert; A Kiermaier; J Seoane; J Lukas; H Karsunky; T Möröy; J Bartek; J Massagué; F Hänel; M Eilers
Journal:  Nat Cell Biol       Date:  2001-04       Impact factor: 28.824

7.  TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b.

Authors:  J Seoane; C Pouponnot; P Staller; M Schader; M Eilers; J Massagué
Journal:  Nat Cell Biol       Date:  2001-04       Impact factor: 28.824

Review 8.  The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond.

Authors:  Andrew P Halestrap; David Meredith
Journal:  Pflugers Arch       Date:  2003-05-09       Impact factor: 3.657

9.  Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

Authors:  Meenakshi Jain; Constadina Arvanitis; Kenneth Chu; William Dewey; Edith Leonhardt; Maxine Trinh; Christopher D Sundberg; J Michael Bishop; Dean W Felsher
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

10.  A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.

Authors:  Zirong Li; Sara Van Calcar; Chunxu Qu; Webster K Cavenee; Michael Q Zhang; Bing Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

View more
  139 in total

Review 1.  Targeting Cancer Metabolism and Current Anti-Cancer Drugs.

Authors:  Witchuda Sukjoi; Jarunya Ngamkham; Paul V Attwood; Sarawut Jitrapakdee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model.

Authors:  Xiaowen Guan; Mark A Bryniarski; Marilyn E Morris
Journal:  AAPS J       Date:  2018-11-05       Impact factor: 4.009

3.  The MYC mRNA 3'-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels.

Authors:  Francesca R Dejure; Nadine Royla; Steffi Herold; Jacqueline Kalb; Susanne Walz; Carsten P Ade; Guido Mastrobuoni; Jens T Vanselow; Andreas Schlosser; Elmar Wolf; Stefan Kempa; Martin Eilers
Journal:  EMBO J       Date:  2017-04-13       Impact factor: 11.598

4.  Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer.

Authors:  John T Cunningham; Melissa V Moreno; Alessia Lodi; Sabrina M Ronen; Davide Ruggero
Journal:  Cell       Date:  2014-05-22       Impact factor: 41.582

5.  MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.

Authors:  Chunxiao Yan; Fan Yang; Chunxia Zhou; Xuejun Chen; Xuechuan Han; Xueqin Liu; Hongyun Ma; Wei Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

6.  Monocarboxylate transporter 1 inhibitors as potential anticancer agents.

Authors:  Shirisha Gurrapu; Sravan K Jonnalagadda; Mohammad A Alam; Grady L Nelson; Mary G Sneve; Lester R Drewes; Venkatram R Mereddy
Journal:  ACS Med Chem Lett       Date:  2015-03-19       Impact factor: 4.345

7.  [Small interfering RNA-mediated monocarboxylate transporter 1 silencing enhances sensitivity of nasopharyngeal carcinoma HNE1/DDP cells to cisplatin-induced apoptosis].

Authors:  Pei Zhang; Fang Liu; Jiao Gao; Lin-Yan Ma; Xiao-Jin Sun; Hai-Lun Zheng; Hao Liu; Su-Rong Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

8.  Lactic Acid Accumulation in the Tumor Microenvironment Suppresses 18F-FDG Uptake.

Authors:  Silvan Türkcan; Louise Kiru; Dominik J Naczynski; Laura S Sasportas; Guillem Pratx
Journal:  Cancer Res       Date:  2018-12-03       Impact factor: 12.701

Review 9.  MYC, Metabolism, and Cancer.

Authors:  Zachary E Stine; Zandra E Walton; Brian J Altman; Annie L Hsieh; Chi V Dang
Journal:  Cancer Discov       Date:  2015-09-17       Impact factor: 39.397

10.  Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer.

Authors:  Jennifer M Johnson; Stephen Y Lai; Paolo Cotzia; David Cognetti; Adam Luginbuhl; Edmund A Pribitkin; Tingting Zhan; Mehri Mollaee; Marina Domingo-Vidal; Yunyun Chen; Barbara Campling; Voichita Bar-Ad; Ruth Birbe; Madalina Tuluc; Ubaldo Martinez Outschoorn; Joseph Curry
Journal:  Semin Oncol       Date:  2015-09-24       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.